FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial-Reference-Cited by-同舟云学术

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

Published:2014-09 Issue:10 Volume:15 Page:1065-1075
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Heinemann Volker,von Weikersthal Ludwig Fischer,Decker Thomas,Kiani Alexander,Vehling-Kaiser Ursula,Al-Batran Salah-Eddin,Heintges Tobias,Lerchenmüller Christian,Kahl Christoph,Seipelt Gernot,Kullmann Frank,Stauch Martina,Scheithauer Werner,Hielscher Jörg,Scholz Michael,Müller Sebastian,Link Hartmut,Niederle Norbert,Rost Andreas,Höffkes Heinz-Gert,Moehler Markus,Lindig Reinhard U,Modest Dominik P,Rossius Lisa,Kirchner Thomas,Jung Andreas,Stintzing Sebastian

Publisher

Elsevier BV

Subject

Oncology

Reference24 articles.

1. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer;Van Cutsem;N Engl J Med,2009

2. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status;Van Cutsem;J Clin Oncol,2011

3. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer;Hurwitz;N Engl J Med,2004

4. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience;Bokemeyer;Proc Am Soc Clin Oncol,2008

5. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience;Van Cutsem;Proc Am Soc Clin Oncol,2008

Cited by 1482 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between sidedness and survival among chemotherapy refractory metastatic colorectal cancer patients treated with trifluridine/tipiracil or regorafenib;The Oncologist;2024-09-07

2. Triplet chemotherapy with or without bevacizumab as first line treatment for metastatic colorectal cancer: An AGEO multicenter real-world study;Digestive and Liver Disease;2024-09

3. Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI;ESMO Open;2024-09

4. First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial;Med;2024-09

5. Investigation on the cost–effectiveness of Cetuximab in treatment of colorectal cancer: a systematic review;Colorectal Cancer;2024-08-27